We recently compiled a list of the 10 Most Undervalued Dow Stocks to Buy Now. Merck & Co., Inc. is among the most undervalued ...

Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

Merck MRK announced that the FDA has accepted the two supplemental biologics license applications (sBLAs) seeking approval ...

In a phase 2 study, researchers added pembrolizumab to chemoradiation and surgery for muscle-invasive bladder cancer. 60 ...

FDA grants Priority Review to enfortumab vedotin plus pembrolizumab for cisplatin-eligible MIBC based on KEYNOTE-B15 data showing a 47% reduction in EFS risk.

FDA grants Priority Review for Padcev plus Keytruda in muscle-invasive bladder cancer, showing improved survival and reduced ...

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

Pfizer (PFE) and Astellas (ALPMF) (ALPMY) announced Monday that the FDA has granted priority review for their marketing application, which seeks U.S. approval for their antibody drug conjugate, Padcev ...

Merck (MRK) stock climbed 3% after FDA granted priority review for KEYTRUDA bladder cancer treatment combination, with ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...